|Bid||6.75 x 0|
|Ask||7.00 x 0|
|Day's Range||6.95 - 6.95|
|52 Week Range||3.20 - 14.90|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.71|
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. Presentation Details: Piper Sandler 34th Annual Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, November 30, 2022Time: 10:30 a.m. ET / 7:30 a.
Shareholders in Sutro Biopharma, Inc. ( NASDAQ:STRO ) may be thrilled to learn that the analysts have just delivered a...
The average of price targets set by Wall Street analysts indicates a potential upside of 213.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.